Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.81 |
| ▸ | NT5E | P21589 | 1/20 | 0.76 |
| ▸ | KRAS | P01116 | 2/20 | 0.76 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.75 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.71 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.71 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.71 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.71 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.68 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.68 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.68 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.68 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.68 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.66 |
| ▸ | IMPDH2 | P12268 | 5/20 | 0.65 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.65 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gtp SCHEMBL18271799 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| Gtp SCHEMBL3333959 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL376140 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| Gtp SCHEMBL18784960 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL376139 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL1304258 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL19691775 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL2593095 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| Gtp SCHEMBL5809658 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| Gtp SCHEMBL17367368 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1405 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260061039-A1 | PRODUCTION OF 2-3-CYCLIC GMP-AMP (cGAMP) AND METHOD OF USE THEREOF | UNIV COLORADO REGENTS (US) | 2026-03-05 | — | — | US | claimed |
| EP-3752610-B1 | POLYRIBONUCLEOTIDE CONTAINING DEUTERATED NUCLEOTIDES | ETHRIS GMBH (DE) | 2026-01-28 | — | — | EP | claimed |
| US-20250378906-A1 | METHODS AND ARRANGEMENTS FOR INTERACTIVE SIMULATION OF XRNA PRODUCTION | ARRANTA BIO HOLDINGS LLC (US) | 2025-12-11 | — | — | US | claimed |
| US-12492234-B2 | Fiber assembly and use thereof | KYOTO UNIVERSITY (JP) | 2025-12-09 | — | — | US | claimed |
| US-20250295658-A1 | ANTIPARASITIC AGENTS AND METHODS | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH | 2025-09-25 | — | — | US | claimed |
| US-20250277180-A1 | APPARATUS, SYSTEMS AND METHODS FOR CONTINUOUS RNA MANUFACTURING | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2025-09-04 | — | — | US | claimed |
| EP-4581169-A2 | METHODS OF ENZYMATICALLY REPAIRING CLEAVED RNAS AND DETECTING THEREOF | The Johns Hopkins University (US) | 2025-07-09 | — | — | EP | claimed |
| US-12280105-B2 | Compositions and methods of mRNA vaccines against novel coronavirus infection | RNAimmune, Inc. (US) | 2025-04-22 | — | — | US | claimed |
| US-12280104-B2 | Composition and methods for MRNA vaccines against novel omicron coronavirus infections | RNAimmune, Inc. (US) | 2025-04-22 | — | — | US | claimed |
| EP-4486909-A2 | RNA MOLECULE | Imperial College Innovations Limited (GB) | 2025-01-08 | — | — | EP | claimed |
| WO-2001077366-A1 | POSITIVE SELECTION METHOD, COMPOUNDS, HOST CELLS AND USES THEREOF | CUBIST PHARMACEUTICALS, INC. (US) | 2001-10-18 | — | — | WO | claimed |
| EP-1025115-A1 | NOVEL NUCLEOSIDE OR NUCLEOTIDE FLUORESCENT CONJUGATES, PREPARATION METHOD AND USES | CIS BIO INTERNATIONAL (FR) | 2000-08-09 | — | — | EP | claimed |
| WO-1999018114-A1 | NOVEL NUCLEOSIDE OR NUCLEOTIDE FLUORESCENT CONJUGATES, PREPARATION METHOD AND USES | CIS BIO INTERNATIONAL (FR) | 1999-04-15 | — | — | WO | claimed |
| WO-1996011398-A1 | PROCESS FOR ASSESSING TUBULIN PROTEIN POLYMERIZATION | MERCK & CO., INC. (US) | 1996-04-18 | — | — | WO | claimed |
| WO-1995024497-A2 | ENZYMATIC PREPARATION OF POLYSACCHARIDES | FIDIA ADVANCED BIOPOLYMERS S.R.L. (IT) | 1995-09-14 | — | — | WO | claimed |
| EP-0090417-B1 | PROCESS FOR PRODUCING 3'-DEOXYGUANOSINE | Yamasa Shoyu Kabushiki Kaisha (JP) | 1989-03-01 | — | — | EP | claimed |
| US-4594321-A | Reacting guanine derivative with phosphate | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1986-06-10 | — | — | US | claimed |
| US-4594320-A | Reacting guanine derivative with phosphate compound | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1986-06-10 | — | — | US | claimed |
| US-4577012-A | ABSORPTION ON ACTIVATED CARBON, ELUTION WITH ALKALI HYDROXIDE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1986-03-18 | — | — | US | claimed |
| EP-0090417-A2 | Process for producing 3'-deoxyguanosine | Yamasa Shoyu Kabushiki Kaisha (JP) | 1983-10-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260061039-A1 | PRODUCTION OF 2-3-CYCLIC GMP-AMP (cGAMP) AND METHOD OF USE THEREOF | CGAS, PDE11A, PDE3B | TGM2 853/4885NT5E 88/4885KRAS 4776/4885 |
| US-12280104-B2 | Composition and methods for MRNA vaccines against novel omicron coronavirus infections | RBM22, RNGTT, RBM25 | TGM2 3045/4885NT5E 930/4885KRAS 1393/4885 |
| US-12280105-B2 | Compositions and methods of mRNA vaccines against novel coronavirus infection | RNGTT, SARS1, ACE2 | TGM2 766/4885NT5E 1065/4885KRAS 810/4885 |
| US-20250295658-A1 | ANTIPARASITIC AGENTS AND METHODS | DHFR, DHODH, MTHFD1 | TGM2 108/4885NT5E 402/4885KRAS 3461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.